Skip to main content
Aarti Pharmalabs Limited logo

Aarti Pharmalabs Limited — Investor Relations & Filings

Ticker · AARTIPHARM ISIN · INE0LRU01027 LEI · 335800TTAKRBNDK5P363 BSE.NS Manufacturing
Open in API
Filings indexed 244 across all filing types
Latest filing 2026-05-25 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS AARTIPHARM

About Aarti Pharmalabs Limited

https://www.aartipharmalabs.com/

Aarti Pharmalabs Limited is a manufacturer of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and xanthine derivatives. The company specializes in the development and production of complex chemistry-based products for the global pharmaceutical and generic drug industries. Its core portfolio includes APIs across diverse therapeutic areas such as oncology, cardiovascular, and anti-diabetics. Additionally, the company is a major producer of xanthines, including caffeine and theophylline. Aarti Pharmalabs offers comprehensive Contract Development and Manufacturing Organization (CDMO) services, leveraging its integrated research and development capabilities and large-scale manufacturing facilities. The organization maintains high regulatory standards, ensuring compliance with international quality benchmarks to serve a global clientele.

Recent filings

Filing Released Lang Actions
Dividend
Interim / Quarterly Report Classification · 84% confidence The document is the official SEBI Regulation 30 & 33 filing of Aarti Pharmalabs’ audited financial results. It contains full standalone and consolidated financial statements for the quarter and financial year ended March 31, 2026 (income statement, balance sheet, cash flow, notes, auditor’s report) rather than merely high-level highlights. This makes it a substantive interim/quarterly report (Q4 results) with actual financial data, not just an earnings snapshot or just a publication notice. Therefore it best fits the Interim/Quarterly Report category (IR). FY 2026
2026-05-25 English
Outcome of the Board meeting held on 25th May, 2026
Interim / Quarterly Report Classification · 80% confidence The document is an official board meeting “Outcome of Board Meeting” notice filed under SEBI (LODR) Regulations, 2015, to BSE and NSE, enclosing the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2026, along with the Statement of Assets & Liabilities, Cash Flow Statement, Auditor’s Report, and related notes. It contains comprehensive financial statements for a period shorter than and including the fiscal year (i.e., quarterly and year‐end results) and not just a high‐level summary. This matches the definition of an Interim/Quarterly Report (IR), which requires substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, the filing should be classified as an IR. FY 2026
2026-05-25 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 89% confidence The document is a filing under Regulation 30 and 33 of SEBI (LODR) Regulations, 2015 to notify the stock exchanges of the Board’s approval of the audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2026. It includes the full set of audited financial statements (statement of profit & loss, balance sheet, cash flow statement, auditor’s report, and notes) rather than merely announcing that a report will be published. It is not a full Annual Report (10-K) with MD&A, nor a short announcement or certification alone. Therefore it qualifies as a periodic financial report containing substantive financial data and is best classified as an Interim/Quarterly Report under our taxonomy. FY 2026
2026-05-25 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 90% confidence The document is a formal notice to stock exchanges under SEBI LODR Regulation 30, informing of an upcoming investor/analyst conference event. It does not contain any financial results, minutes, presentation materials, or transcripts—merely a compliance announcement. There is no indication of a full report being attached or published. As such, it is a general regulatory filing (fallback category).
2026-05-20 English
Intimation of Conference Call
Regulatory Filings Classification · 80% confidence The document is an intimation under Regulation 30 of the SEBI (LODR) Regulations notifying stock exchanges about an upcoming investor/analyst meeting. It does not contain financial results, transcripts, or substantive report content but is a routine compliance announcement. This falls under general regulatory filings (RNS).
2026-05-20 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 85% confidence The document is a compliance announcement under Regulation 30 of SEBI (LODR) Regulations notifying the stock exchanges of an upcoming earnings conference call. It contains no actual financial results or presentation materials, but rather a regulatory intimation/notice. This fits the definition of a general regulatory filing (RNS) rather than an earnings release, transcript, or report itself.
2026-05-20 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.